Drug Profile
Siramesine
Alternative Names: LU-28179Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Developer Lundbeck A/S; Valerio Therapeutics
- Class Antidepressants; Anxiolytics; Indoles; Spiro compounds
- Mechanism of Action Sigma-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Cancer; Major depressive disorder
Most Recent Events
- 04 Sep 2014 Discontinued - Preclinical for Cancer in Denmark (PO)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
- 17 Sep 2008 Siramesine is still in preclinical trials for Cancer in Denmark